Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avadel Pharmaceuticals plc

9.01
+0.12001.35%
Post-market: 9.010.00000.00%17:10 EDT
Volume:1.07M
Turnover:9.49M
Market Cap:871.62M
PE:-32.88
High:9.02
Open:8.81
Low:8.69
Close:8.89
Loading ...

Company Profile

Company Name:
Avadel Pharmaceuticals plc
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
188
Office Location:
10 Earlsfort Terrace,Dublin 2,Ireland
Zip Code:
D02 T380
Fax:
- -
Introduction:
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Directors

Name
Position
Gregory J. Divis
Chief Executive Officer and Director
Geoffrey M. Glass
Chair of the Board
Eric J. Ende
Director
Linda S. Palczuk
Director
Mark A. McCamish
Director
Peter Thornton
Director

Shareholders

Name
Position
Gregory J. Divis
Chief Executive Officer and Director
Thomas S. McHugh
Chief Financial Officer
Richard Kim
Chief Commercial Officer